Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
Key facts
- Where
- Shenyang, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07252401, who can take part
Where in China
- Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)Shenyang, ChinaContact: Xingshun Qi, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- General Hospital of Shenyang Military Region
- Trial code
- NCT07252401
- Record updated
- 27 August 2026
- Original description
Acute upper gastrointestinal bleeding (AUGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AVB complicated by renal dysfunction (RD). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AVB complicated by RD.Read full original descriptionShow less
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction: A Multicenter Randomized Controlled Trial
Acute upper gastrointestinal bleeding (AUGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AVB complicated by renal dysfunction (RD). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AVB complicated by RD.
Inclusion: patients have a definite diagnosis of live cirrhosis and AVB; patients present with renal dysfunction at admission; patients' age 18-70 years old; patients or relatives can sign the informed consent form.
Exclusion: patients received kidney replacement therapy before enrollment; patients have contraindications for experimental drugs; patients participated in other clinical studies within 3 months before enrollment; patients have non-variceal upper gastrointestinal bleeding; patients have hepatorenal syndrome- acute renal injury (HRS-AKI); patients have chronic kidney disease; patients have a history of liver transplantation or TIPS; patients have acute liver failure or acute-on-chronic liver failure; patients have hepatic or renal malignant tumor; patients have severe diseases of the heart, lungs, and brain; patients have other conditions that investigators deem unsuitable for enrollment in the study; patients have structural kidney injury; patients are in pregnancy or lactation.